A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group

Maurizio Brausi, J. Alfred Witjes, Donald Lamm, Raj Persad, Joan Palou, Marc Colombel, Roger Buckley, Mark Soloway, Hideyuki Akaza, Andreas Böhle

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Purpose: Although the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines all provide an excellent evidence-based framework for the management of nonmuscle invasive bladder cancer, these guidelines vary with respect to important issues such as risk level definitions and management strategies for these risk categories. Therefore, we built on the existing framework provided by current guidelines, and provide consensus on the definitions of low, intermediate and high risk nonmuscle invasive bladder cancer, as well as practical recommendations for the treatment of patients in each of these risk categories. Materials and Methods: An international committee of experts on bladder cancer management identified and analyzed the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines as well as the published English language literature related to the treatment and management of nonmuscle invasive bladder cancer available as of April 2010. Results: Based on review of the current guidelines and literature, the International Bladder Cancer Group developed practical recommendations for the management of nonmuscle invasive bladder cancer. Conclusions: Complete transurethral bladder tumor resection is recommended for all patients with nonmuscle invasive bladder cancer. For low risk disease a single, immediate chemotherapeutic instillation after transurethral bladder tumor resection is recommended. For intermediate or high risk disease there is no significant benefit from an immediate, postoperative chemotherapeutic instillation. For intermediate risk disease intravesical bacillus Calmette-Guérin with maintenance or intravesical chemotherapy is recommended. For high risk disease bacillus Calmette-Guérin induction plus maintenance is recommended. The appropriate management of recurrence depends on the patient level of risk as well as previous treatment, while the management of treatment failure depends on the type of failure as well as the level of risk for recurrence and disease progression.

Original languageEnglish
Pages (from-to)2158-2167
Number of pages10
JournalJournal of Urology
Volume186
Issue number6
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Practice Management
Practice Guidelines
Urinary Bladder Neoplasms
Guidelines
Bacillus
Referral and Consultation
Maintenance
Recurrence
Risk Management
Treatment Failure
Disease Progression
Neoplasms
Consensus
Language
Therapeutics
Drug Therapy

Keywords

  • administration
  • clinical protocols
  • drug therapy
  • intravesical
  • mycobacterium bovis
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. / Brausi, Maurizio; Witjes, J. Alfred; Lamm, Donald; Persad, Raj; Palou, Joan; Colombel, Marc; Buckley, Roger; Soloway, Mark; Akaza, Hideyuki; Böhle, Andreas.

In: Journal of Urology, Vol. 186, No. 6, 01.12.2011, p. 2158-2167.

Research output: Contribution to journalArticle

Brausi, M, Witjes, JA, Lamm, D, Persad, R, Palou, J, Colombel, M, Buckley, R, Soloway, M, Akaza, H & Böhle, A 2011, 'A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group', Journal of Urology, vol. 186, no. 6, pp. 2158-2167. https://doi.org/10.1016/j.juro.2011.07.076
Brausi, Maurizio ; Witjes, J. Alfred ; Lamm, Donald ; Persad, Raj ; Palou, Joan ; Colombel, Marc ; Buckley, Roger ; Soloway, Mark ; Akaza, Hideyuki ; Böhle, Andreas. / A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. In: Journal of Urology. 2011 ; Vol. 186, No. 6. pp. 2158-2167.
@article{53301f8028144812a4560c80c212dc4e,
title = "A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group",
abstract = "Purpose: Although the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines all provide an excellent evidence-based framework for the management of nonmuscle invasive bladder cancer, these guidelines vary with respect to important issues such as risk level definitions and management strategies for these risk categories. Therefore, we built on the existing framework provided by current guidelines, and provide consensus on the definitions of low, intermediate and high risk nonmuscle invasive bladder cancer, as well as practical recommendations for the treatment of patients in each of these risk categories. Materials and Methods: An international committee of experts on bladder cancer management identified and analyzed the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines as well as the published English language literature related to the treatment and management of nonmuscle invasive bladder cancer available as of April 2010. Results: Based on review of the current guidelines and literature, the International Bladder Cancer Group developed practical recommendations for the management of nonmuscle invasive bladder cancer. Conclusions: Complete transurethral bladder tumor resection is recommended for all patients with nonmuscle invasive bladder cancer. For low risk disease a single, immediate chemotherapeutic instillation after transurethral bladder tumor resection is recommended. For intermediate or high risk disease there is no significant benefit from an immediate, postoperative chemotherapeutic instillation. For intermediate risk disease intravesical bacillus Calmette-Gu{\'e}rin with maintenance or intravesical chemotherapy is recommended. For high risk disease bacillus Calmette-Gu{\'e}rin induction plus maintenance is recommended. The appropriate management of recurrence depends on the patient level of risk as well as previous treatment, while the management of treatment failure depends on the type of failure as well as the level of risk for recurrence and disease progression.",
keywords = "administration, clinical protocols, drug therapy, intravesical, mycobacterium bovis, urinary bladder neoplasms",
author = "Maurizio Brausi and Witjes, {J. Alfred} and Donald Lamm and Raj Persad and Joan Palou and Marc Colombel and Roger Buckley and Mark Soloway and Hideyuki Akaza and Andreas B{\"o}hle",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.juro.2011.07.076",
language = "English",
volume = "186",
pages = "2158--2167",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group

AU - Brausi, Maurizio

AU - Witjes, J. Alfred

AU - Lamm, Donald

AU - Persad, Raj

AU - Palou, Joan

AU - Colombel, Marc

AU - Buckley, Roger

AU - Soloway, Mark

AU - Akaza, Hideyuki

AU - Böhle, Andreas

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Purpose: Although the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines all provide an excellent evidence-based framework for the management of nonmuscle invasive bladder cancer, these guidelines vary with respect to important issues such as risk level definitions and management strategies for these risk categories. Therefore, we built on the existing framework provided by current guidelines, and provide consensus on the definitions of low, intermediate and high risk nonmuscle invasive bladder cancer, as well as practical recommendations for the treatment of patients in each of these risk categories. Materials and Methods: An international committee of experts on bladder cancer management identified and analyzed the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines as well as the published English language literature related to the treatment and management of nonmuscle invasive bladder cancer available as of April 2010. Results: Based on review of the current guidelines and literature, the International Bladder Cancer Group developed practical recommendations for the management of nonmuscle invasive bladder cancer. Conclusions: Complete transurethral bladder tumor resection is recommended for all patients with nonmuscle invasive bladder cancer. For low risk disease a single, immediate chemotherapeutic instillation after transurethral bladder tumor resection is recommended. For intermediate or high risk disease there is no significant benefit from an immediate, postoperative chemotherapeutic instillation. For intermediate risk disease intravesical bacillus Calmette-Guérin with maintenance or intravesical chemotherapy is recommended. For high risk disease bacillus Calmette-Guérin induction plus maintenance is recommended. The appropriate management of recurrence depends on the patient level of risk as well as previous treatment, while the management of treatment failure depends on the type of failure as well as the level of risk for recurrence and disease progression.

AB - Purpose: Although the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines all provide an excellent evidence-based framework for the management of nonmuscle invasive bladder cancer, these guidelines vary with respect to important issues such as risk level definitions and management strategies for these risk categories. Therefore, we built on the existing framework provided by current guidelines, and provide consensus on the definitions of low, intermediate and high risk nonmuscle invasive bladder cancer, as well as practical recommendations for the treatment of patients in each of these risk categories. Materials and Methods: An international committee of experts on bladder cancer management identified and analyzed the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines as well as the published English language literature related to the treatment and management of nonmuscle invasive bladder cancer available as of April 2010. Results: Based on review of the current guidelines and literature, the International Bladder Cancer Group developed practical recommendations for the management of nonmuscle invasive bladder cancer. Conclusions: Complete transurethral bladder tumor resection is recommended for all patients with nonmuscle invasive bladder cancer. For low risk disease a single, immediate chemotherapeutic instillation after transurethral bladder tumor resection is recommended. For intermediate or high risk disease there is no significant benefit from an immediate, postoperative chemotherapeutic instillation. For intermediate risk disease intravesical bacillus Calmette-Guérin with maintenance or intravesical chemotherapy is recommended. For high risk disease bacillus Calmette-Guérin induction plus maintenance is recommended. The appropriate management of recurrence depends on the patient level of risk as well as previous treatment, while the management of treatment failure depends on the type of failure as well as the level of risk for recurrence and disease progression.

KW - administration

KW - clinical protocols

KW - drug therapy

KW - intravesical

KW - mycobacterium bovis

KW - urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=80755172266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755172266&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.07.076

DO - 10.1016/j.juro.2011.07.076

M3 - Article

VL - 186

SP - 2158

EP - 2167

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -